Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis.

MLA

Thorburn, Douglas, et al. “Serologic Extracellular Matrix Remodeling Markers Are Related to Fibrosis Stage and Prognosis in a Phase 2b Trial of Simtuzumab in Patients with Primary Sclerosing Cholangitis.” Hepatology Communications, 2024. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1449576322&authtype=sso&custid=ns315887.

APA

Thorburn, D., Thorburn, D., Leeming, D., Barchuk, W., Wang, Y., Lu, X., Malkov, V., Ito, K., Bowlus, C., Levy, C., Goodman, Z., Karsdal, M., Muir, A., & Xu, J. (2024). Serologic extracellular matrix remodeling markers are related to fibrosis stage and prognosis in a phase 2b trial of simtuzumab in patients with primary sclerosing cholangitis. Hepatology Communications.

Chicago

Thorburn, Douglas, Douglas Thorburn, Diana Leeming, William Barchuk, Ya Wang, Xiaomin Lu, Vladislav Malkov, et al. 2024. “Serologic Extracellular Matrix Remodeling Markers Are Related to Fibrosis Stage and Prognosis in a Phase 2b Trial of Simtuzumab in Patients with Primary Sclerosing Cholangitis.” Hepatology Communications. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1449576322&authtype=sso&custid=ns315887.